Am­gen dis­con­tin­ues prostate can­cer drug in $650M write­down, as obe­si­ty pipeline comes in­to fo­cus in 2024

Am­gen is tak­ing a $650 mil­lion im­pair­ment charge from its ac­qui­si­tion of Teneo­bio, the biotech gi­ant said Tues­day, as it shelves an ex­per­i­men­tal prostate can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER